Skip to main content
. 2021 May 13;28(3):1847–1856. doi: 10.3390/curroncol28030171

Figure 3.

Figure 3

Cost-effectiveness acceptability curve (CEAC) for probabilistic model comparing 12-Versus 4-weekly BTA treatment showing the probability of 12-Versus 4-weekly BTA treatment being cost-effective at various willingness-to-pay thresholds.